



RECEIVED

FEB 02 2001

TECH CENTER 1600/2000

GAU1644

\$

Patent Docket P1467R2

PTT5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |  |
|---|--|
| In re Application of<br><br>Camellia W. Adams et al.<br><br>Serial No.: 09/602,812<br><br>Filed: June 23, 2000<br><br>For: Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies   | Group Art Unit: 1644<br><br>Examiner: not yet assigned |
| <p><b>CERTIFICATE OF MAILING</b><br/>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>January 24, 2001</p> <p><i>Ann Savelli</i><br/>Ann Savelli</p> |  |

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- 37 CFR §1.97(b)
- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
  - within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
  - before the mailing of the first Office action on the merits; or
  - before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.
- 37 CFR §1.97(c)
- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.
- 37 CFR §1.97(d)
- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37